Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

From diabetes to dentistry: metformin targets mitochondrial-immune crosstalk to restore periodontal homeostasis

Wu M., Wang F., Zhang Y., Xing A., Li Z., Lu X.

Narrative Review on Chronic Inflammation, published in J Transl Med (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
J Transl Med (2026)
Reported sample size
—
Source database
Europe PMC
PMID
41721327
PMCID
PMC13032262
DOI
10.1186/s12967-026-07772-4

Abstract (original English)

BACKGROUND: Metformin (MET), a first-line antidiabetic agent, exhibits significant therapeutic potential for periodontitis management due to its multifaceted pharmacological actions. MAIN BODY: This review synthesizes current evidence on MET’s antimicrobial, anti-inflammatory, and osteogenic properties in the context of periodontitis. Mechanistically, MET primarily targets mitochondrial Complex I, inhibiting ATP production and activating AMPK. This AMPK activation enhances microtubule dynamics via CLIP170 phosphorylation, thereby boosting the bactericidal capacity of neutrophils and macrophages. Furthermore, MET suppresses mTOR signaling, which promotes M2 macrophage polarization, regulates autophagic flux, and inhibits NLRP3-mediated pyroptosis, collectively mitigating periodontal inflammation and tissue damage. In the realm of bone regeneration, MET upregulates key osteogenic markers and improves alveolar bone volume in preclinical models. Recent translational advances are focusing on the development of localized MET delivery systems, such as hydrogels, electrospun fibers, and MET-functionalized scaffolds, to enhance therapeutic efficacy at the site of disease. CONCLUSIONS: MET represents a promising multifunctional agent for periodontitis therapy, effectively bridging antimicrobial and regenerative therapeutic strategies. However, several challenges remain, including the nee

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
MitochondriaPeriodontiumAnimalsHumansPeriodontitisDiabetes MellitusMetforminDentistryHomeostasis

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research